tesamorelin ipamorelin peptide – Research TESAMORELIN IPAMORELIN 10mg/3mg – Fountain

Applications Claiming Priority (3) Related Parent Applications (2) Publications (2) Family ID=42288881 Family Applications (2) Family Applications Before (1) Country Status (14) Families Citing this family (64) Citations (6) Family Cites Families (935) 2010 2010-02-19 TR TR2019/08314T patent/TR201908314T4/en unknown 2010-02-19 AU AU2010216512A patent/AU2010216512B2/en active Active 2010-02-19 EP EP10705204.5A patent/EP2398500B1/en active Active 2010-02-19 PT PT181770397T patent/PT3395372T/en unknown 2010-02-19 US US13/202,704 patent/US20110305751A1/en not_active Abandoned 2010-02-19 DK DK10705204.5T patent/DK2398500T3/en active 2010-02-19 DK DK18177039.7T patent/DK3395372T3/en active 2010-02-19 CA CA2969926A patent/CA2969926C/en active Active 2010-02-19 CA CA2752373A patent/CA2752373C/en active Active 2010-02-19 WO PCT/NL2010/050082 patent/WO2010095940A2/en not_active Ceased 2010-02-19 ES ES10705204T patent/ES2728225T3/en active Active 2010-02-19 ES ES18177039T patent/ES2919563T3/en active Active 2010-02-19 PL PL10705204T patent/PL2398500T3/en unknown 2010-02-19 CN CN201410377000.3A patent/CN104208718B/en active Active 2010-02-19 JP JP2011551026A patent/JP5564517B2/en active Active 2010-02-19 CN CN201080008108.5A patent/CN102316902B/en active Active 2010-02-19 EP EP18177039.7A patent/EP3395372B1/en active Active 2010-02-19 HU HUE18177039A patent/HUE059078T2/en unknown 2010-02-19 PT PT10705204T patent/PT2398500T/en unknown 2010-02-19 NZ NZ616673A patent/NZ616673A/en unknown 2010-02-19 PL PL18177039.7T patent/PL3395372T3/en unknown 2010-02-19 NZ NZ594310A patent/NZ594310A/en not_active IP Right Cessation 2014 2014-03-18 US US14/217,713 patent/US20140227185A1/en not_active Abandoned 2014-06-16 JP JP2014123346A patent/JP5961219B2/en active Active 2016 2016-03-04 JP JP2016042232A patent/JP6267735B2/en not_active Expired - Fee Related 2016-09-27 AU AU2016234891A patent/AU2016234891B2/en active Active

Cancer Cell 42 , 119134.e12 (2024)

6 Egrifta Medication Guide / NCBI BookshelfCommon adverse effects, contraindications (active malignancy, pregnancy, mannitol hypersensitivity), IGF-1 monitoring and site rotation

The efficient penetration of CTS-SeNPs into cells and tissues prevents the accumulation of ROS and lipofuscin (LF), protects GPX activity, and decreases selenium in vitro and in vivo cytotoxicity